• Sobi snags FDA nod for rare disease drug Gamifant fiercepharma
    November 22, 2018
    Several months after scooping up global rights to emapalumab in a $452 million deal, Sobi has won approval for the drug to treat certain patients with primary hemophagocytic lymphohistiocytosis.
PharmaSources Customer Service